Please ensure Javascript is enabled for purposes of website accessibility Investing in the next wave of innovative medicines - Janus Henderson Investors
For financial professionals in Luxembourg

Investing in the next wave of innovative medicines

In our latest panel discussion portfolio manager Andy Acker, research analyst Agustin Mohedas, scientist Dr. Stephen Harrison and Akero's CEO Andrew Cheng, detailed the remarkable advances in disease categories that previously had limited treatment options, like NASH, a severe form of nonalcoholic fatty liver disease.

WEBCAST: Investing in the next wave of innovative medicines

Andy Acker, CFA

Andy Acker, CFA

Portfolio Manager


Agustin Mohedas, PhD

Agustin Mohedas, PhD

Portfolio Manager | Research Analyst


27 Apr 2023
52 minute watch

JHI

JHI

These are the views of the author at the time of publication and may differ from the views of other individuals/teams at Janus Henderson Investors. References made to individual securities do not constitute a recommendation to buy, sell or hold any security, investment strategy or market sector, and should not be assumed to be profitable. Janus Henderson Investors, its affiliated advisor, or its employees, may have a position in the securities mentioned.

 

Past performance does not predict future returns. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.

 

The information in this article does not qualify as an investment recommendation.

 

There is no guarantee that past trends will continue, or forecasts will be realised.

 

Marketing Communication.

 

Glossary

 

 

 

Andy Acker, CFA

Andy Acker, CFA

Portfolio Manager


Agustin Mohedas, PhD

Agustin Mohedas, PhD

Portfolio Manager | Research Analyst


27 Apr 2023
52 minute watch